Chemometec A/ (CHEMM.CO) traded down -0.42 % during a 24 hours period ending at 04:34 PM Central Europe on Monday 26th. One Chemometec A/ stock can currently be bought for about DKK 609.5 on popular exchanges. Current supply of Chemometec A/ stocks is 17.2 mn. Chemometec A/ has a current market capitalization of DKK 10.2 bn and approximately DKK 16.4 mn worth of Chemometec A/ was traded on exchanges in the last 24 hours. Since last month end, Chemometec A/ has traded 12.86 % up. Simple moving average of last 200 days is at DKK 443.64. The highest price of past 52 weeks was recorded at DKK 804 on 10/30/2025. 52 weeks low was at DKK 235.2 on 03/24/2026.

Summary of the latest news for Chemometec A/

CHEMOMETEC A/S appears among a list of Danish companies that have recently attracted short‑seller interest, according to a market overview published by ProInvestor. The report, drawing on data from the Danish Financial Supervisory Authority, shows the firm with a modest short‑position relative to other listed entities. No further commentary or performance details are provided within the source.

Here is how related stocks have performed in the past 24 hours:

  • Boozt (BOOZT.ST) traded down -1.02 % and now trades at SEK 159. Boozt has a market capitalisation of SEK 9.3 bn. Current price/earnings ratio for Boozt is 32.97. Boozt AB has received a modest lift in analyst expectations following a review of its recent financial disclosures. The company’s updated outlook prompted several research houses to raise their target prices, maintaining a purchase recommendation. Market commentary noted a slight decline in Boozt’s share price during the trading session, with the stock trading below its recent highs. Analysts highlighted the company’s ongoing efforts to strengthen its market position, though no specific valuation figures were disclosed. Overall, the update reflects a cautious yet positive view of Boozt’s future prospects, underscored by the consensus to hold a buy stance amid evolving market conditions.

  • Sp A/ (SPG.CO) traded down -0.33 % and now trades at DKK 459. Sp A/ has a market capitalisation of DKK 5.3 bn. Sp A/ has a current price to earnings ratio of 16.15.

  • Scandinavian Tobacco (STG.CO) traded down -1.42 % and now trades at DKK 76.4. Scandinavian Tobacco has a market capitalisation of DKK 6 bn. Scandinavian Tobacco has a current price to earnings ratio of 9.44. SCANDINAVIAN TOBACCO GROUP A has been reported as one of the Danish-listed companies with a modest short‑position presence. In a recent overview of short positions in the Danish market, the tobacco group was noted with a net short stake of under one percent, reflecting a relatively low level of bearish sentiment compared with its peers. The data, compiled from regulatory filings, places the company among a broader range of firms that are subject to short‑selling activity, but it does not indicate any extraordinary market pressure or unusual volatility. The report suggests that the group’s equity remains comparatively stable, with short‑selling activity that is typical for mid‑cap firms in the region.

  • Dfds A/ (DFDS.CO) traded down -1.29 % and now trades at DKK 158.9. Current market capitalisation for Dfds A/ is DKK 8.3 bn.

  • Embla Medical Hf (EMBLA.CO) traded up 1.34 % and now trades at DKK 27.2. Current market capitalisation for Embla Medical Hf is DKK 11.3 bn. Embla Medical Hf has a current price to earnings ratio of 18.14.

About Chemometec A/

Chemometec A/S is a health care company operating in the life sciences tools and services sector. Established in 1997, it has its main operations at its headquarters located in Allerod, Denmark. The company specializes in designing, developing, and producing instruments for various applications in cell counting and evaluation. These include automated cell counters and viability analyzers such as NucleoCounter NC-3000, an advanced image cytometer to characterize cell properties; NucleoCounter NC-250, an automated cell analyzer to characterize cell properties; NucleoCounter NC-200, an automated cell counter that provides solutions for cell counting and cell viability determinations; NucleoCounter NC-100, a mammalian cell counter; NucleoCounter SP-100, a sperm cell counter that offers total sperm concentration and sperm viability in a semen sample from ejaculates or extended doses; NucleoCounter YC-100, a yeast cell counter used to measure the total cell count and viability of yeast cells in suspension; NucleoCounter SCC-100, a somatic cell counter for measuring the amount of somatic cells in a milk sample; and NucleoCounter SCC-400, a somatic cell counter for determining the number of somatic cells in a milk sample. Additionally, the company offers Xcyto, a quantitative cell imager to analyze adherent and suspension cells; NucleoView, a software that serves as the user interface for the NucleoCounter NC-200, NC-250, and NC-3000 instruments, handling data acquisition, image analysis, and data presentation; consumables including cassettes, reagents, slides, and test kits; and accessories including cables, power supplies, software, and other products. ChemoMetec A/S’s solutions are applied in various areas such as cell therapeutic, stem cell research, cancer cell research, bioprocessing, toxicology, cell biology research, sperm cell counting, yeast cell counting, and somatic cell counting.